Login Register Cart 0
Generic placeholder image

Current Women`s Health Reviews

Editor-in-Chief

ISSN (Print): 1573-4048
ISSN (Online): 1875-6581

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

Harnessing Immunologic Tools to Treat Gynecologic Disorders

Author(s): John Yeh

Volume 19, Issue 2, 2023

Published on: 20 October, 2022

Article ID: e201022210226 Pages: 2

DOI: 10.2174/157340481902221020115126

Price: $65

[1]
Weiner G. Building better monoclonal antibody-based therapeutics. Nat Rev Cancer 2015; 15: 361-70.
[http://dx.doi.org/10.1038/nrc3930]
[2]
Lu RM, Hwang YC, Liu IJ, et al. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci 2020; 27: 1.
[http://dx.doi.org/10.1186/s12929-019-0592-z]
[3]
Hauser A, Attwood M, Rask-Andersen M, et al. Trends in GPCR drug discovery: new agents, targets and indications. Nat Rev Drug Discov 2017; 16: 829-42.
[http://dx.doi.org/10.1038/nrd.2017.178]
[4]
Hutchings C, Koglin M, Olson W, et al. Opportunities for therapeutic antibodies directed at G-protein-coupled receptors. Nat Rev Drug Discov 2017; 16: 787-810.
[http://dx.doi.org/10.1038/nrd.2017.91]
[5]
Khetan R, Dharmayanti C, Gillam TA, et al. Using GPCRs as Molecular Beacons to Target Ovarian Cancer with Nanomedicines. Cancers 2022; 14(10): 2362.
[http://dx.doi.org/10.3390/cancers14102362]
[6]
Ghaly HSA, Varamini P. New drug delivery strategies targeting the GnRH receptor in breast and other cancers. Endocr Relat Cancer 2021; 28(11): R251-69.
[http://dx.doi.org/10.1530/ERC-20-0442] [PMID: 34236041]
[7]
Bejar FG, Oaknin A, Williamson C, et al. Novel Therapies in Gynecologic Cancer. Am Soc Clin Oncol Educ Book 2022; Apr;42:: 1-17.
[http://dx.doi.org/10.1200/EDBK_351294] [PMID: 35594502]
[8]
Rubinstein MM, Makker V. Optimizing immunotherapy for gynecologic cancers. Curr Opin Obstet Gynecol 2020; 32(1): 1-8.
[http://dx.doi.org/10.1097/GCO.0000000000000603] [PMID: 31833942] [PMCID: PMC8135258]
[9]
Lynam S, Lugade AA, Odunsi K. Immunotherapy for Gynecologic Cancer: Current Applications and Future Directions. Clin Obstet Gynecol 2020; 63(1): 48-63.
[http://dx.doi.org/10.1097/GRF.0000000000000513] [PMID: 31833846] [PMCID: PMC7298668]
[10]
Pakish JB, Jazaeri AA. Immunotherapy in Gynecologic Cancers: Are We There Yet? Curr Treat Options Oncol 2017; 18: 59.
[http://dx.doi.org/10.1007/s11864-017-0504-y]
[11]
Avila AM, Bebenek I, Bonzo JA, et al. An FDA/CDER perspective on nonclinical testing strategies: Classical toxicology approaches and new approach methodologies (NAMs). Regul Toxicol Pharmacol 2020; 114104662 Epub 2020 Apr 20
[http://dx.doi.org/10.1016/j.yrtph.2020.104662] [PMID: 32325112]
[12]
M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals. U.S. Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Center for Biologics Evaluation and Research (CBER). January 2010. ICH 1 http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm
[13]
http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm
[14]
Ryman JT, Meibohm B. Pharmacokinetics of Monoclonal Antibodies. CPT Pharmacometrics Syst Pharmacol 2017; 6(9): 576-88. Epub 2017 Jul 29
[http://dx.doi.org/10.1002/psp4.12224] [PMID: 28653357] [PMCID: PMC5613179]
[15]
Descotes J. Immunotoxicity of monoclonal antibodies. MAbs 2009; Mar-Apr;1(2): 104-11. Epub 2009 Mar 19
[http://dx.doi.org/10.4161/mabs.1.2.7909] [PMID: 20061816] [PMCID: PMC2725414]
[16]
Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJ. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov 2010; Apr;9(4): 325-38. Epub 2010 Mar 22
[http://dx.doi.org/10.1038/nrd3003] [PMID: 20305665]
[17]
Hong D, Sloane DE. Hypersensitivity to monoclonal antibodies used for cancer and inflammatory or connective tissue diseases Ann Allergy Asthma Immunol 2019; Jul;123(1): 35-41. Epub 2019 Apr 25.
[http://dx.doi.org/10.1016/j.anai.2019.04.015] [PMID: 31028896]
[18]
Isabwe GAC, Garcia Neuer M, de Las Vecillas Sanchez L, Lynch DM, Marquis K, Castells M. Hypersensitivity reactions to therapeutic monoclonal antibodies: Phenotypes and endotypes. J Allergy Clin Immunol. 2018; Jul;142(1): 159-170.e2. Epub 2018 Mar 5
[http://dx.doi.org/10.1016/j.jaci.2018.02.018] [PMID: 29518427]
[19]
Demlova R, Valík D, Obermannova R. ZdraŽilová-Dubská L. The safety of therapeutic monoclonal antibodies: implications for cancer therapy including immuno-checkpoint inhibitors. Physiol Res 2016; Dec 2165 (Suppl. 4): S455-62.
[http://dx.doi.org/10.33549/physiolres.933525] [PMID: 28006927]
[20]
Maritaz C, Broutin S, Chaput N, Marabelle A, Paci A. Immune checkpoint-targeted antibodies: a room for dose and schedule optimization? J Hematol Oncol 2022; Jan 15;15(1): 6.
[http://dx.doi.org/10.1186/s13045-021-01182-3] [PMID: 35033167] [PMCID: PMC8760805]
[21]
Matucci A, Vultaggio A, Danesi R. The use of intravenous versus subcutaneous monoclonal antibodies in the treatment of severe asthma: a review. Respir Res 2018; Aug 16;19(1): 154.
[http://dx.doi.org/10.1186/s12931-018-0859-z] [PMID: 30115042] [PMCID: PMC6097430]
[22]
Jackisch C, Müller V, Maintz C, Hell S, Ataseven B. Subcutaneous Administration of Monoclonal Antibodies in Oncology. Geburtshilfe Frauenheilkd 2014; Apr;74(4): 343-9.
[http://dx.doi.org/10.1055/s-0034-1368173] [PMID: 25076790] [PMCID: PMC4078128]
[23]
Pham-Huy A, Top KA, Constantinescu C, Seow CH, El-Chaâr D. The use and impact of monoclonal antibody biologics during pregnancy. CMAJ 2021; Jul 26;193(29): E1129-36.
[http://dx.doi.org/10.1503/cmaj.202391] [PMID: 34312166] [PMCID: PMC8321301]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy